BNGO BIONANO GENOMICS INC

Bionano to Report Second Quarter 2023 Financial Results and Host a Conference Call and Webcast on August 9, 2023

Bionano to Report Second Quarter 2023 Financial Results and Host a Conference Call and Webcast on August 9, 2023

SAN DIEGO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Wednesday, August 9, 2023, at 4:30 p.m. Eastern Time to report financial results for the second quarter 2023 and to highlight recent corporate progress.

Conference Call & Webcast Details

Date:Wednesday, August 9th, 2023
Time:4:30 p.m. ET
Participant Call Link:

Webcast Link:

Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano’s investor relations website at  for at least 30 days.

CONTACTS

Company Contact:

Erik Holmlin, CEO

Bionano Genomics, Inc.

+1 (858) 888-7610

 

Investor Relations:

David Holmes

Gilmartin Group

+1 (858) 888-7625

 



EN
02/08/2023

Underlying

BNGOBIONANO GENOMICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BIONANO GENOMICS INC

 PRESS RELEASE
Free
BNGO BIONANO GENOMIC...

Bionano to Participate in the H.C. Wainwright @ Home Event

Bionano to Participate in the H.C. Wainwright @ Home Event SAN DIEGO, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano’s president and chief executive officer, will participate in the H.C. Wainwright @ Home Event on Wednesday, October 15th, 2025. Conference & Webcast Details Date:October 15, 2025Time:10:00 a.m. to 11:00 a.m. ETPresenter:Erik Holmlin, PhD, CEO of BionanoWebcast:   A replay / recording of the session will be available following the conference through the Bionano website at  for at least 90 days. About ...

October 7, 2025 1 EN
 PRESS RELEASE
Free
BNGO BIONANO GENOMIC...

Bionano Genomics, Inc. Announces Closing of $10 Million Public Offering

Bionano Genomics, Inc. Announces Closing of $10 Million Public Offering SAN DIEGO, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) (“Bionano” or the “Company”) today announced the closing of its previously announced public offering of an aggregate of 5,000,000 shares of the Company’s common stock (or common stock equivalents in lieu thereof), Series E warrants to purchase up to 5,000,000 shares of the Company’s common stock and short-term Series F warrants to purchase up to 5,000,000 shares of the Company’s common stock (all the warrants, collectively, the “Series ...

September 17, 2025 1 EN
 PRESS RELEASE
Free
BNGO BIONANO GENOMIC...

Bionano Genomics, Inc. Announces Pricing of $10 Million Public Offering

Bionano Genomics, Inc. Announces Pricing of $10 Million Public Offering SAN DIEGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) (“Bionano” or the “Company”) today announced the pricing of a public offering of an aggregate of 5,000,000 shares of the Company’s common stock (or common stock equivalents in lieu thereof), Series E warrants to purchase up to 5,000,000 shares of the Company’s common stock and short-term Series F warrants to purchase up to 5,000,000 shares of the Company’s common stock (all the warrants, collectively, the “Series Warrants”), at a combin...

September 16, 2025 1 EN
 PRESS RELEASE
Free
BNGO BIONANO GENOMIC...

Multiple Studies Highlighting OGM Utility For Analysis of Cancer Bioma...

Multiple Studies Highlighting OGM Utility For Analysis of Cancer Biomarker Chromoanagenesis Published in Dedicated Issue of Methods in Molecular Biology SAN DIEGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that an issue of the book series Methods in Molecular Biology dedicated to studies of the catastrophic genome rearrangement known as chromoanagenesis was published with multiple studies highlighting the advantages of optical genome mapping (OGM) in chromoanagenesis research. According to research, chromoanagenesis refers to a catastrophic ...

September 16, 2025 1 EN
 PRESS RELEASE
Free
BNGO BIONANO GENOMIC...

CMS Posts Preliminary Payment Determination for New Category I CPT Cod...

CMS Posts Preliminary Payment Determination for New Category I CPT Code Covering Use of OGM for Constitutional Genetic Disorders SAN DIEGO, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (Nasdaq: BNGO) offering CLIA-certified laboratory developed tests (LDTs) based on optical genome mapping (OGM), today announced that Centers for Medicare & Medicaid Services (CMS) posted the preliminary payment determination for the Category I Current Procedural Terminology (CPT®) code for use of OGM in cytogenomic genome-wide analysis to detec...

September 15, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch